Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study

NCT: NCT05639569 · ACTIVE_NOT_RECRUITING

NCT IDNCT05639569
StatusACTIVE_NOT_RECRUITING
Start Date2023-05-03
Completion2030-12-30

Brief Summary

The purpose of this study is to collect clinical data on patient outcomes, evaluate the safety and performance of Ankura TAA Stent Graft System and Surpass Super Stiff Guidewire, and build clinical evidence for patients with Descending Thoracic Aneurysm (DTA) or Type B Aortic Dissection (TBAD).

Frequently Asked Questions

What is Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study?

Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study is a clinical trial registered under NCT05639569. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05639569?

The current status of NCT05639569 (Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study) is: ACTIVE_NOT_RECRUITING.

When did Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study start?

Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study started on 2023-05-03.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑